Evogene (EVGN) Free Cash Flow (2013 - 2026)
Evogene (EVGN) posted Free Cash Flow of -$3.0 million for Q1 2026, down 10.15% sequentially from -$2.7 million in Q4 2025, and up 41.67% YoY from -$2.1 million in Q1 2025.
Evogene (EVGN) Free Cash Flow (2013 - 2026) Analysis & Trends
Evogene has reported Free Cash Flow for 14 years, with the latest figure at -$3.0 million in Q1 2026.
- Quarterly Free Cash Flow rose 41.67% year-over-year to -$3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.1 million (up 8.47% YoY) and the FY2025 annual result came in at -$13.4 million, up 34.24% from the prior year.
- Free Cash Flow eased to -$3.0 million in Q1 2026 per EVGN's latest filing, from -$2.7 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $7.3 million in Q1 2022 and troughed at -$6.8 million in Q3 2022.
- A 5-year average of -$1.1 million and a median of -$2.7 million in 2025 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Free Cash Flow soared 337.74% in 2023, then tumbled 219.05% in 2025.
- Over 5 years, Free Cash Flow stood at -$2.5 million in 2022, then jumped by 337.74% to $5.8 million in 2023, then slumped by 172.6% to -$4.2 million in 2024, then jumped by 36.78% to -$2.7 million in 2025, then fell by 10.15% to -$3.0 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$3.0 million, -$2.7 million, and -$125000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | -2.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.95 Mn |
| Mar 31, 2026 | -2.95 Mn |
| Dec 31, 2025 | -2.68 Mn |
| Dec 31, 2025 | -2.68 Mn |
| Sep 30, 2025 | -125,000.00 |
| Sep 30, 2025 | -125,000.00 |
| Jun 30, 2025 | -2.31 Mn |
| Jun 30, 2025 | -2.31 Mn |
| Mar 31, 2025 | -5.06 Mn |
| Mar 31, 2025 | -5.06 Mn |
| Dec 31, 2024 | -4.24 Mn |
| Dec 31, 2024 | -4.24 Mn |
| Sep 30, 2024 | -4.96 Mn |
| Sep 30, 2024 | -4.96 Mn |
| Jun 30, 2024 | 5.44 Mn |
| Jun 30, 2024 | 5.44 Mn |
| Mar 31, 2024 | 4.25 Mn |
| Mar 31, 2024 | 4.25 Mn |
| Dec 31, 2023 | 5.84 Mn |
| Dec 31, 2023 | 5.84 Mn |